2′ Biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3540-3544

  Budzik, Brian ^a,b   Garzya, Vincenzo ^a,c   Shi, Dongchuan ^a   Foley, James J ^a   Rivero, Ralph A ^a   Langmead, Christopher J ^a   Watson, Jeannette ^a   Wu, Zining ^a   Forbes, Ian T ^a   Jin, Jian ^a  

^a GLAXOSMITHKLINE   (United States)

^b University of North Carolina at Chapel Hill ^*  (United States)

^c University of North Carolina   (United States)

Author keywords

2 Biaryl amides; Novel M1 agonists; Subtype selective M1 muscarinic acetylcholine receptor agonist

Indexed keywords

2' BIARYL AMIDE; MUSCARINIC M1 RECEPTOR AGONIST; UNCLASSIFIED DRUG; AMIDE; AROMATIC HYDROCARBON; MUSCARINIC M1 RECEPTOR;

ARTICLE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG POTENTIATION; SYNTHESIS;

AMIDES; DRUG DISCOVERY; HYDROCARBONS, AROMATIC; MOLECULAR STRUCTURE; RECEPTOR, MUSCARINIC M1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954217196     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.128     Document Type: Article

References (32)

1. M.P. Caulfield, and N.J.M. Birdsall Pharmacol. Rev. 50 1998 279
2. R.M. Eglen Prog. Med. Chem. 43 2005 105
3. E.C. Hulme, N.J.M. Birdsall, and N.J. Buckley Ann. Rev. Pharmacol. Toxicol. 30 1990 633
4. M.P. Caulfield Pharmacol. Ther. 58 1993 319
5. R.M. Eglen Auto. Autacoid Pharmacol. 26 2006 219
6. A. Fisher, Z. Pittel, R. Haring, N. Bar-Ner, M. Kligerspatz, N. Natan, I. Egozi, H. Sonego, I. Marcovitch, and R. Brandeis J. Mol. Neurosci. 20 2003 349
7. T.A. Spalding, C. Trotter, N. Skjaerbaek, T.L. Messier, E.A. Currier, E.S. Burstein, D. Li, U. Hacksell, and M.R. Brann Mol. Pharmacol. 61 2002 1297
8. C.J. Langmead, V.A.H. Fry, I.T. Forbes, C.L. Branch, A. Christopoulos, M.D. Wood, and H. Hedron Mol. Pharmacol. 69 2006 236
9. C.K. Jones, A.E. Brady, A.A. Davis, Z. Xiang, M. Bubser, M.N. Tantawy, A. Kane, T.M. Bridges, J.P. Kennedy, S.R. Bradley, T. Peterson, R.M. Baldwin, R. Kessler, A. Deutch, A.I. Levey, C.W. Lindsley, and P.J. Conn J. Neurosci. 28 2008 10422
10. T.M. Bridges, A.E. Brady, J.P. Kennedy, R.N. Daniels, N.R. Miller, K. Kim, M.L. Breininger, P.R. Gnetry, J.T. Brogan, C.K. Jones, P.J. Conn, and C.W. Lindsley Bioorg. Med. Chem. Lett. 18 2008 5439
11. N.R. Miller, R.N. Daniels, T.M. Bridges, A.E. Brady, P.J. Conn, and C.W. Lindsley Bioorg. Med. Chem. Lett. 18 2008 5443
12. 2-5 subtype selectivity. For FLIPR assay details, see: Budzik, B. W; Cooper, D. G.; Forbes, I. F.; Jin, J.; Shi, D.; Smith, P. W.; Walker, G. R. WO Patent 2007036711-A1, 2007
13. Chem. Abstr. 2007, 146, 401966.
14. 50 value in molarity.
15. Full experimental procedures are available in Supplementary data detailing the preparation of 1 via the route of Scheme 1.
16. P. Reynard, M. Robber, and R.C. Moreau Bull. Soc. Chim. Fr. 1962 1735
17. 1H NMR.
18. J. Jin, T.L. Graybill, M.A. Wang, L.D. Davis, and M.L. Moore J. Comb. Chem. 3 2001 97
19. Available from Polymer Laboratories, part number: 1466-6689, 150-300 μm, 1.5 mmol/g loading.
20. 16 below).
21. +.
22. Significant amounts of byproduct with reduction of Boc to methyl was produced in step(s) c of Scheme 4.
23. For method of step (i) in Scheme 4, see: M. Allegretti, V. Berdini, M.C. Cesta, R. Curti, L. Nicolini, and A. Topai Tetrahedron Lett. 42 2001 4257
24. Compound 4c was ∼50:50 cis to trans, 4b was 80:20 cis to trans (by NMR studies). Compound 4a was made in one step by EDC, HOAt coupling of commercially available 3′-chlorobiphenyl-2-carboxylic acid and 1-methyl-4-(aminomethyl)piperidine.
25. For preparation of the amide starting material for 5d in Scheme 5, see: S.M. Jenkins, H.J. Wadsworth, S. Bromidge, B.S. Orlek, P.A. Wyman, G.J. Riley, and J. Hawkins J. Med. Chem. 35 1992 2392
26. For preparation of the ketone starting material for 5e in Scheme 5, see: G.K. Myoung, E.T. Bodor, C. Wang, T.K. Harden, and H. Kohn J. Med. Chem. 46 2003 2216
27. 50 = 7.0, IA = 74%.
28. 2O) followed by EDC, HOAt coupling with 3′-chlorobiphenyl-2- carboxylic acid.
29. 3, DME, 80 °C, 4 h) followed by hydrolysis (NaOH, MeOH, reflux 1 h).
30. 2-5 and showed no agonist activity.
31. J.N. Heinrich, J.A. Butera, T. Carrick, A. Kramer, D. Kowal, T. Lock, K.L. Marquis, M.H. Pausch, M. Popiolek, S.C. Sun, E. Tseng, A.J. Uveges, and S.C. Mayer Eur. J. Pharmacol. 605 2009 53
32. N.R. Mirza, D. Peters, and R.G. Sparks CNS Drug Rev. 9 2003 159